Cargando…
Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis
BACKGROUND: Positioning infliximab (IFX), cyclosporine and tacrolimus (TAC) for treating ulcerative colitis (UC) is in great debate. METHODS: A literature search identified studies that investigated IFX vs. cyclosporine or IFX vs TAC in UC patients. Short-term remission, short-term, 1-year and 3-yea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598782/ https://www.ncbi.nlm.nih.gov/pubmed/33126341 http://dx.doi.org/10.1097/MD.0000000000022894 |
_version_ | 1783602711222026240 |
---|---|
author | Jia, Xuemei Guo, Ruitong Hu, Zhenbiao Liu, Jianxin Liu, Jianping Li, Bolin Yang, Qian He, Jianming |
author_facet | Jia, Xuemei Guo, Ruitong Hu, Zhenbiao Liu, Jianxin Liu, Jianping Li, Bolin Yang, Qian He, Jianming |
author_sort | Jia, Xuemei |
collection | PubMed |
description | BACKGROUND: Positioning infliximab (IFX), cyclosporine and tacrolimus (TAC) for treating ulcerative colitis (UC) is in great debate. METHODS: A literature search identified studies that investigated IFX vs. cyclosporine or IFX vs TAC in UC patients. Short-term remission, short-term, 1-year and 3-year colectomy rate were employed as primary end-points to assess efficacy. Odds ratios (ORs) with 95% confidence intervals (CIs) were analyzed. RESULTS: Overall, 15 studies comprised 596 patients in IFX group and 866 in calcineurin inhibitors group (644 received cyclosporine and 222 received TAC). No significant difference was seen between IFX and calcineurin inhibitors with regard to short-term remission. IFX led to a lower short-term (OR: 0.59, 95% CI: 0.43–0.82, P:.001), 1-year (OR: 0.53, 95% CI: 0.38–0.73, P < .001), 3-year colectomy (OR: 0.41, 95% CI: 0.20–0.84, P:.02) than calcineurin inhibitors. IFX led to a lower short-term (OR: 0.51, 95% CI: 0.36–0.71, P < .001), 1-year (OR: 0.53, 95% CI: 0.37–0.74, P:.003) colectomy and a trend of lower 3-year colectomy (OR: 0.49, 95% CI: 0.22–1.06, P:.07) than cyclosporine while no significant difference was seen between IFX and TAC. Results of network meta-analysis showed that the order was cyclosporine, TAC and IFX from high rate to low with regard to short-term and 1-year colectomy. CONCLUSION: IFX treatment leads to a lower short-term, 1-year colectomy rate and a trend of lower 3-year colectomy rate in UC patients than cyclosporine while no significant difference is seen between IFX and TAC. TAC may be superior than cyclosporine with regard to efficacy based on indirect comparisons. Randomized trials with fixed protocol are warranted to identify the optimal medical strategy in patients with UC. |
format | Online Article Text |
id | pubmed-7598782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75987822020-11-02 Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis Jia, Xuemei Guo, Ruitong Hu, Zhenbiao Liu, Jianxin Liu, Jianping Li, Bolin Yang, Qian He, Jianming Medicine (Baltimore) 4500 BACKGROUND: Positioning infliximab (IFX), cyclosporine and tacrolimus (TAC) for treating ulcerative colitis (UC) is in great debate. METHODS: A literature search identified studies that investigated IFX vs. cyclosporine or IFX vs TAC in UC patients. Short-term remission, short-term, 1-year and 3-year colectomy rate were employed as primary end-points to assess efficacy. Odds ratios (ORs) with 95% confidence intervals (CIs) were analyzed. RESULTS: Overall, 15 studies comprised 596 patients in IFX group and 866 in calcineurin inhibitors group (644 received cyclosporine and 222 received TAC). No significant difference was seen between IFX and calcineurin inhibitors with regard to short-term remission. IFX led to a lower short-term (OR: 0.59, 95% CI: 0.43–0.82, P:.001), 1-year (OR: 0.53, 95% CI: 0.38–0.73, P < .001), 3-year colectomy (OR: 0.41, 95% CI: 0.20–0.84, P:.02) than calcineurin inhibitors. IFX led to a lower short-term (OR: 0.51, 95% CI: 0.36–0.71, P < .001), 1-year (OR: 0.53, 95% CI: 0.37–0.74, P:.003) colectomy and a trend of lower 3-year colectomy (OR: 0.49, 95% CI: 0.22–1.06, P:.07) than cyclosporine while no significant difference was seen between IFX and TAC. Results of network meta-analysis showed that the order was cyclosporine, TAC and IFX from high rate to low with regard to short-term and 1-year colectomy. CONCLUSION: IFX treatment leads to a lower short-term, 1-year colectomy rate and a trend of lower 3-year colectomy rate in UC patients than cyclosporine while no significant difference is seen between IFX and TAC. TAC may be superior than cyclosporine with regard to efficacy based on indirect comparisons. Randomized trials with fixed protocol are warranted to identify the optimal medical strategy in patients with UC. Lippincott Williams & Wilkins 2020-10-30 /pmc/articles/PMC7598782/ /pubmed/33126341 http://dx.doi.org/10.1097/MD.0000000000022894 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 4500 Jia, Xuemei Guo, Ruitong Hu, Zhenbiao Liu, Jianxin Liu, Jianping Li, Bolin Yang, Qian He, Jianming Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis |
title | Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis |
title_full | Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis |
title_fullStr | Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis |
title_full_unstemmed | Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis |
title_short | Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis |
title_sort | efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: a meta-analysis |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598782/ https://www.ncbi.nlm.nih.gov/pubmed/33126341 http://dx.doi.org/10.1097/MD.0000000000022894 |
work_keys_str_mv | AT jiaxuemei efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT guoruitong efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT huzhenbiao efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT liujianxin efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT liujianping efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT libolin efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT yangqian efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis AT hejianming efficacyofinfliximabcyclosporineandtacrolimusonulcerativecolitisametaanalysis |